Research Articles | Page 9 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

  1. Home
  2. Research

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria Oct 2023 Annals of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study Oct 2023 Leukemia Aplastic Anemia
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes Oct 2023 Oncologist Myelodysplastic Syndromes (MDS)
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) Oct 2023 Journal of Clinical Oncology Myelodysplastic Syndromes (MDS)
A Journey from Blood Cells to Genes and Back Aug 2023 Annual Review of Genomics and Human Genetics Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria Aug 2023 Haematologica Paroxysmal Nocturnal Hemoglobinuria (PNH)
Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria Jul 2023 Blood Reviews Paroxysmal Nocturnal Hemoglobinuria (PNH)
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study Jul 2023 American Journal of Hematology Paroxysmal Nocturnal Hemoglobinuria (PNH)
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? Jul 2023 Lancet Myelodysplastic Syndromes (MDS)
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial Jul 2023 Lancet Myelodysplastic Syndromes (MDS)